Resources

BIA’s influence and connect were out in force last week – grasping a timely opportunity to get our key Autumn Budget asks across impactfully to the Chancellor with the clear backing of over 200 member CEOs, and putting on a dynamic, pro-innovation Future of UK Regulation conference, featuring MHRA and NICE CEOs amongst other key stakeholders.

As discussion around the Autumn Budget heats up, BIA is leading a unified call to the Chancellor to back the science, the entrepreneurs and the life sciences industry that can fuel transformational growth for the UK economy. Our sector letter highlights key growth levers and indeed the barriers that hold the sector back in already challenging global conditions. 

AAVantgarde's Stargardt disease and Usher syndrome Ib programmes address the root genetic causes of devastating conditions and offer hope of improvement to patients and families living with progressive vision loss.

Thermo Fisher Scientific Inc. announced a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven, for $8.875 billion.

The UK biotech financing numbers for Q3 are out, showing validation of UK assets but a sector under strain from prolonged global headwinds. Time to double down on investment in innovation as a driver for growth and deploy Industrial Strategy plans with urgency.

LifeArc and the Gates Foundation are funding seven ground-breaking new projects launched to lower the cost of monoclonal antibody production to make them more accessible globally.

New BIA data shows venture capital activity slowing amid the longest global funding drought in the sector. Despite a landmark M&A deal validating UK science, the figures signal a fragile moment that needs urgent government action.

​​​​​​​Following a landmark TechBio Week, we reflect with some insights from our flagship conference on the transformative potential for growth of technological advances in the sector.

Cyclana Bio announced the close of a £5 million pre-seed funding round, co-led by NfX and Eka VC, and including Cocoa VC, Wilbe, and Angel investors.

Major 2025 deals from Isomorphic Labs and CHARM Therapeutics validate the sector's maturity as it calls for domestic capital to close the 'scale-up gap.' 

It’s TechBio week and we’re celebrating the UK’s leading role in AI and life sciences with significant investment and interest from global players and our own flagship TechBio UK conference and 2025 report launch. 

How are pharmaceutical companies, policymakers and investors seeking growth amid fast-changing international politics, trade deals, a looming patent cliff, and technological innovation? Our maiden Life sciences and healthcare insights report offers a global perspective on disruptive forces from artificial intelligence to regulatory shifts.

In this blog, NRG Therapeutics co-founder and CEO Dr Neil Miller and Parkinson’s UK Director of Research (and Investor Observer to NRG), Professor David Dexter, explore the history of the relationship and the innovation journey to date.

Good to see support for BIA agendas in government messaging as we continue to push for pension fund reform, attracting the best global talent, UK manufacturing resilience and addressing the challenges of scaling.

Ellie Avni, Senior Director in Employment Tax and Reward at FTI Consulting, explores how the new PISCES platform could reshape EMI and CSOP share option plans – creating fresh opportunities for flexibility and tax-efficient value realisation.

New Moderna Innovation and Technology Centre opened as government further boosts life sciences sector with £50 million fund.